Shares in Cytori fall as it announces suspension of heart disease trial
Shares in USA-based regenerative medicine company Cytori Therapeutics (Nasdaq: CYTX) declined as much as 29% as it announced it was suspending enrolment in its Athena and Athena II trials, testing its adipose-derived regenerative cell therapy in ischemic heart disease patients.
This means it will not be possible to complete enrolment on the Athena I trial before the end of 2014, as Cytori had previously anticipated.
The company decided to put the trials on hold on the basis of a safety review of reported cerebrovascular events, where symptoms occurred in three patients. Two of those have seen their symptoms fully resolved within a short period, and the third has had a substantial resolution of symptoms, but Cytori has nonetheless decided to suspend trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze